spacer
home > ebr > summer 2018 > calibrating expectations
PUBLICATIONS
European Biopharmaceutical Review

Calibrating Expectations

In Europe and the US, biosimilar drugs are gaining acceptance among physicians, payers, and patients in areas such as kidney disease, growth disorders, cancer, and auto-immune conditions. Progress has been slower in diabetes, but the pandemic nature and heavy cost burdens of the illness may fuel demand for biosimilars in the future. Examining the track record of follow-on biologics in other therapeutic areas can suggest constructive ways to envision the future for diabetes.

By many measures, the global epidemic in diabetes dwarfs other public health challenges. An estimated 60 million Europeans and 30 million Americans have diabetes today. In the US, about 1.5 million people are diagnosed with the disease each year. Many of them patients have transitioned from prediabetes, which affects 84 million Americans. The economic toll is also difficult to ignore.

Direct medical costs linked to diabetes come to about $237 billion a year in the US – more than for any other illness. Insulin and other anti-diabetic drugs, along with treatments for complications, make up 45% of total direct costs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rafal Kokolus brings to Syneos Health more than 10 years of combined pharma consulting and drug development/commercialisation experience. He has supported several major pharma and biotech companies in maximising the commercial value of pipeline and in-line assets and optimising marketing and brand strategy. Rafal earned an MBA from University of Western Ontario’s Richard Ivey School of Business, Canada, and a BSc in cell biology and genetics from the University of British Columbia, Canada, and a Graduate Diploma in business administration from Simon Fraser University, Canada.

Dr Doug Niven specialises in pricing and market access at Syneos Health where he has been for the last six years. Prior to this, Doug worked within PwC’s Healthcare Strategy practice. Doug holds a PhD in physics from the University of Birmingham, UK, and a BSc in economics and finance from the University of London, UK.

Rohit Sood leads the global commercial strategy and planning practice at Syneos Health Consulting. During his 12 years at Syneos, he has advised clients in the areas of portfolio planning, commercialisation and launch excellence, and corporate strategy. Rohit has worked with several clients helping them think through their biosimilar go-to-market strategy.
spacer
Rafal Kokolus
spacer
spacer
spacer
Dr Doug Niven
spacer
spacer
spacer
Rohit Sood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Change of Company Name: VTU Technology is now VALIDOGEN

VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

Biotech Showcase™ 2019

7-9 January 2019, Hilton San Francisco Union Square

Biotech Showcase™ is an investor and networking conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement